Want to see TSE:TLT full AI Analyst Report?
Theralase Technologies (TLT) Stock Statistics & Valuation Metrics
Total Valuation
Theralase Technologies has a market cap or net worth of CAD 55.89M. The enterprise value is CAD 67.31M.
- Market Cap
- CAD 55.89M
- Enterprise Value
- CAD 67.31M
Share Statistics
Theralase Technologies has 310,483,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 310,483,300
- Owned by Insiders
- 6.10%
- Owned by Institutions
- 0.03%
Financial Efficiency
Theralase Technologies’s return on equity (ROE) is -2.32 and return on invested capital (ROIC) is -186.74%.
- Return on Equity (ROE)
- -2.32
- Return on Assets (ROA)
- -1.18
- Return on Invested Capital (ROIC)
- -186.74%
- Return on Capital Employed (ROCE)
- -2.23
- Revenue Per Employee
- 51.03K
- Profits Per Employee
- -257.55K
- Employee Count
- 16
- Asset Turnover
- 0.23
- Inventory Turnover
- 1.14
Valuation Ratios
The current PE Ratio of Theralase Technologies is -12.68. Theralase Technologies’s PEG ratio is -0.63.
- PE Ratio
- -12.68
- PS Ratio
- 69.64
- PB Ratio
- 7.47
- Price to FCF
- -16.59
- Price to Operating Cash Flow
- -15.08
- PEG Ratio
- -0.63
Income Statement
In the last 12 months, Theralase Technologies had revenue of 816.47K and earned -4.12M in profits. Earnings per share was -0.02.
- Revenue
- 816.47K
- Gross Profit
- 241.51K
- Operating Income
- -4.18M
- Pretax Income
- -4.12M
- Net Income
- -4.12M
- EBITDA
- -3.91M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was -3.39M and capital expenditures 21,446, giving a free cash flow of -3.37M billion.
- Operating Cash Flow
- -3.39M
- Free Cash Flow
- -3.37M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Theralase Technologies pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.03%
- Earnings Yield
- -7.42%
Stock Price Statistics
- Beta
- -0.00
- 52-Week Price Change
- -12.20%
- 50-Day Moving Average
- 0.18
- 200-Day Moving Average
- 0.24
- Relative Strength Index (RSI)
- 42.67
- Average Volume (3m)
- 246.75K
Important Dates
Theralase Technologies upcoming earnings date is Dec 02, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 28, 2026
- Next Earnings Date
- Dec 02, 2026
- Ex-Dividend Date
- ―
Financial Position
Theralase Technologies as a current ratio of 1.25, with Debt / Equity ratio of 25.76%
- Current Ratio
- 1.25
- Quick Ratio
- 0.94
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -0.07
- Interest Coverage Ratio
- -99.25
Taxes
In the past 12 months, Theralase Technologies has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Theralase Technologies EV to EBITDA ratio is -14.38, with an EV/FCF ratio of -15.07.
- EV to Sales
- 63.27
- EV to EBITDA
- -14.38
- EV to Free Cash Flow
- -15.07
- EV to Operating Cash Flow
- -14.98
Balance Sheet
Theralase Technologies has CAD 5.26M in cash and marketable securities with CAD 148.72K in debt, giving a net cash position of CAD 5.11M billion.
- Cash & Marketable Securities
- CAD 5.26M
- Total Debt
- CAD 148.72K
- Net Cash
- CAD 5.11M
- Net Cash Per Share
- CAD 0.02
- Tangible Book Value Per Share
- CAD 0.02
Margins
Gross margin is 44.21%, with operating margin of -474.33%, and net profit margin of -472.48%.
- Gross Margin
- 44.21%
- Operating Margin
- -474.33%
- Pretax Margin
- -472.48%
- Net Profit Margin
- -472.48%
- EBITDA Margin
- -440.16%
- EBIT Margin
- -466.81%
Analyst Forecast
The average price target for Theralase Technologies is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -24.86%
- EPS Growth Forecast
- 18.29%
Scores
- Smart Score
- 2
- AI Score
- 43